Germacranolide sesquiterpene lactone / COX2/PTGS2 Cancer Research Results

GSL, Germacranolide sesquiterpene lactone: Click to Expand ⟱
Features:
A germacranolide sesquiterpene lactone (GSL) was isolated from Siegesbeckia glabrescens

Germacranolide — Germacranolides are a structural subclass of plant-derived sesquiterpene lactones built on a ten-membered germacrane ring fused to a lactone moiety.

Primary mechanisms (ranked):

  1. Inhibition of Hedgehog effector signaling through suppression of GLI-mediated transcription, including reduced GLI1 expression.
  2. Suppression of cyclin D1 downstream of GLI, producing reduced proliferation of Hedgehog-dependent pancreatic cancer cells.
  3. Inhibition of inflammatory mediator production, including nitric oxide and prostaglandin E2, with reduced inducible nitric oxide synthase and cyclooxygenase-2 expression in activated macrophages.
  4. Electrophilic modification of protein thiols through the α-methylene-γ-lactone pharmacophore is a plausible class-level mechanism for many germacranolides, but direct target engagement has not been established for this specific S. glabrescens GSL.

Bioavailability / PK relevance: No compound-specific absorption, distribution, metabolism, excretion, plasma-exposure, or oral-bioavailability data were identified for the S. glabrescens GSL. Sesquiterpene lactones commonly have poor aqueous solubility, chemical reactivity, rapid metabolism, and nonspecific thiol binding that may limit systemic exposure and therapeutic index. Pharmacokinetic findings from geraniol, germacrone, costunolide, or other germacranolides should not be assigned to this compound.

In-vitro vs systemic exposure relevance: The anticancer experiments used approximately 1–20 µM GSL for transcriptional assays and up to 20 µM for protein analyses; reported proliferation IC50 values were approximately 5.1 µM in AsPC-1 cells and higher in nonmalignant C3H10T1/2 cells. Whether these concentrations are achievable or sustainable in humans is unknown because no human or animal systemic-exposure data were reported. The evidence is therefore concentration-driven and restricted principally to cell culture.

Clinical evidence status: Preclinical only. Evidence for the specific S. glabrescens GSL consists primarily of biochemical and cell-culture studies in pancreatic cancer cells, mesenchymal reporter cells, and activated macrophages. No clinical trials, approved indications, validated dosing regimen, or human anticancer efficacy data were identified. Other germacranolides have broader preclinical anticancer literature, but that evidence cannot be generalized directly to this compound.

Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Hedgehog GLI transcription ↓ GLI transcriptional activity
↓ GLI1		 ↓ Shh-induced differentiation signaling in C3H10T1/2 cells R–G Suppresses the terminal transcriptional output of Hedgehog signaling Central demonstrated mechanism. Activity was observed in GLI reporter systems and PANC-1 and AsPC-1 pancreatic cancer cells. The precise molecular binding target upstream of GLI remains unidentified.
2 Cyclin D1 cell-cycle signaling ↓ cyclin D1
↓ proliferation		 ↔ or less sensitive (model-dependent) G Restricts proliferative cell-cycle progression Cyclin D1 reduction is consistent with inhibition of GLI-dependent transcription. Formal phase-specific arrest was not comprehensively characterized.
3 Pancreatic cancer cell viability ↓ PANC-1 proliferation
↓ AsPC-1 proliferation		 ↓ at higher concentrations G Concentration-dependent antiproliferative activity AsPC-1 cells showed an IC50 near 5 µM, whereas C3H10T1/2 cells were less sensitive. Selectivity remains preliminary and was not established in vivo.
4 Inflammatory nitric oxide signaling Not adequately established ↓ nitric oxide
↓ inducible nitric oxide synthase (context-dependent)		 G Reduces macrophage inflammatory mediator production Demonstrated in LPS-activated RAW264.7 macrophages. This is an anti-inflammatory finding and should not automatically be interpreted as an anticancer mechanism.
5 Prostaglandin E2 and cyclooxygenase-2 Not demonstrated for the specific compound ↓ prostaglandin E2
↓ cyclooxygenase-2 (context-dependent)		 G Suppresses inflammatory prostaglandin synthesis The Nestronics COX-2 entry is supportable through the macrophage study, but not through the listed rosmarinic acid and ginsenoside Rg1 paper.
6 PI3K AKT signaling ↔ phosphorylated AKT and total AKT Not established R–G No detected modulation under the tested conditions Supports a GLI-directed effect that was independent of measurable AKT suppression in PANC-1 cells.
7 Electrophilic thiol reactivity Potential covalent protein modulation (context-dependent) Potential off-target protein binding and sensitization P–R Class-level Michael-acceptor activity The α-methylene-γ-lactone group can react with cysteine thiols. This may contribute to biological activity but also creates selectivity and toxicity constraints. Direct protein targets have not been confirmed for this GSL.
8 Clinical Translation Constraint In-vitro activity only Human safety unknown G Uncertain systemic feasibility No compound-specific PK, formulation, animal efficacy, clinical trial, or therapeutic dose data. Poor solubility, reactive electrophilicity, and possible sesquiterpene-lactone hypersensitivity are relevant class concerns.

P: 0–30 min    R: 30 min–3 hr    G: >3 hr
COX2/PTGS2, cycloocygenase-2 (Cox-2) mRNA and Cox-2 protein: Click to Expand ⟱
Source: HalifaxProj(inhibit)
Type:
Cyclooxygenase-2 (COX-2) is an enzyme that plays a critical role in the conversion of arachidonic acid to prostaglandins, which are lipid compounds involved in various physiological processes, including inflammation, pain, and fever. COX-2 is an inducible enzyme, meaning its expression is typically low in normal tissues but can be upregulated in response to inflammatory stimuli, growth factors, and certain oncogenic signals.
-Cyclooxygenase-2 (COX-2), the rate-limiting enzyme in prostaglandin biosynthesis, plays a key role in inflammation and circulatory homeostasis.
-COX-2 is an inducible enzyme that is upregulated in response to pro-inflammatory signals, including cytokines (e.g., IL-1β, TNF-α) and growth factors.

COX-2 is often overexpressed in various tumors, including colorectal, breast, lung, and prostate cancers.
The prostaglandins produced by COX-2, particularly prostaglandin E2 (PGE2), have several effects that can facilitate cancer progression:
Cell Proliferation: PGE2 can promote the proliferation of cancer cells by activating signaling pathways such as the PI3K/Akt and MAPK pathways.
Nonselective NSAIDs, such as aspirin and ibuprofen, inhibit both COX-1 and COX-2. Epidemiological studies have suggested that regular use of NSAIDs may reduce the risk of certain cancers, particularly colorectal cancer.
Drugs specifically targeting COX-2, such as celecoxib, have been developed.

COX-2 and xanthine oxidase are ROS-producing pro-oxidant enzymes that contribute to inflammation. Elevated COX‑2 levels, often found in inflammatory conditions or certain types of cancers, can contribute to increased production of ROS.
Scientific Papers found: Click to Expand⟱
1048- RosA,  GSL,    Rosmarinic acid in combination with ginsenoside Rg1 suppresses colon cancer metastasis via co-inhition of COX-2 and PD1/PD-L1 signaling axis
- in-vivo, Colon, MC38
TumCMig↓, TumCI↓, PD-1↓, COX2/PTGS2↓, PD-L1↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Migration(tgid=13) ⓘ

TumCI↓, 1,   TumCMig↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   PD-1↓, 1,   PD-L1↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

PD-L1↓, 1,  
Total Targets: 6

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: COX2/PTGS2, cycloocygenase-2 (Cox-2) mRNA and Cox-2 protein
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:86  Target#:66  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page